Table 2.
Relationship between demographic and clinical variables and the occurrence of HIV-sensory neuropathy.
| Variables | SN present N = 126 |
SN absent N = 197 |
P value |
|---|---|---|---|
| Mean age ± SD, years | 38.2 ± 10.6 | 35.8 ± 9.1 | 0.03 |
| Male (N = 105) | 48 (45.7%) | 57 (54.3%) | 0.09 |
| Female (N = 218) | 78 (35.8%) | 140 (64.2%) | |
| Mean height ± SD, metres | 1.62 ± 0.08 | 1.60 ± 0.08 | 0.15 |
| HAART treated (N = 142) | 60 (42.3%) | 82 (57.7%) | 0.29 |
| HAART naïve (N = 181) | 66 (36.5%) | 115 (63.5%) | |
| Mean duration of HAART ± SD, months* | 15.9 ± 9.4 | 16.9 ± 11.6 | 0.59 |
| Stavudine-based HAART (N = 12) | 10 (83.3%) | 2 (16.7%) | 0.003** |
| Non-stavudine-based HAART (N = 130) | 50 (38.5%) | 80 (61.5%) | |
| Mean CD4 count ± SD, cells/mm3 | 180.9 ± 138.2 | 236.0 ± 159.0 | 0.002 |
| Median CD4 count ± SD, cells/mm3 | 165.5 | 185.0 | |
| CD4 count ≤ 200, cells/mm3 (N = 176) | 74 (42.0%) | 102 (58.0%) | 0.22 |
| CD4 count >200, cells/mm3 (N = 147) | 52 (35.4%) | 95 (64.6%) |
*Duration of therapy for the 142 participants on HAART therapy. **Fisher's exact P value.